Holen Sie sich die Stockscreener-App
14.11
19.27%
-3.33
Schlusskurs vom Vortag:
$17.44
Offen:
$17.68
24-Stunden-Volumen:
304.26K
Relative Volume:
3.67
Marktkapitalisierung:
$101.74M
Einnahmen:
$100.44M
Nettoeinkommen (Verlust:
$-133.16M
KGV:
-0.5477
EPS:
-25.76
Netto-Cashflow:
$-94.85M
1W Leistung:
-20.77%
1M Leistung:
-10.26%
6M Leistung:
+52.55%
1J Leistung:
-14.82%
1-Tages-Spanne:
$13.08
$17.98
1-Wochen-Bereich:
$13.08
$19.14
52-Wochen-Spanne:
$5.005
$19.14
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
Firmenname
Atara Biotherapeutics Inc
Sektor
Branche
Telefon
805-623-4211
Adresse
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Vergleichen Sie ATRA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
14.11 | 125.75M | 100.44M | -133.16M | -94.85M | -25.76 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.19 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
810.84 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
408.64 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
815.91 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.19 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-11-09 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-11-09 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-11-09 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-07-20 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-07-13 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-07-13 | Herabstufung | Stifel | Buy → Hold |
| 2022-05-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-05-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-12-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-08 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-30 | Eingeleitet | Evercore ISI | Outperform |
| 2020-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-23 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-11-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-09-27 | Herabstufung | Goldman | Neutral → Sell |
| 2019-09-16 | Herabstufung | Jefferies | Buy → Hold |
| 2019-06-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2019-05-30 | Eingeleitet | ROTH Capital | Buy |
| 2019-05-23 | Eingeleitet | Stifel | Buy |
| 2019-01-23 | Eingeleitet | Mizuho | Buy |
| 2018-04-10 | Eingeleitet | JP Morgan | Overweight |
| 2018-03-16 | Eingeleitet | Guggenheim | Neutral |
| 2018-03-05 | Bestätigt | Jefferies | Buy |
| 2018-02-28 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-02-15 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-01-03 | Hochstufung | Citigroup | Sell → Neutral |
| 2017-10-06 | Fortgesetzt | Goldman | Neutral |
Alle ansehen
Atara Biotherapeutics Inc Aktie (ATRA) Neueste Nachrichten
Why Atara Biotherapeutics Inc. stock could be next big winnerJuly 2025 Sentiment & Weekly High Conviction Ideas - ulpravda.ru
Why Atara Biotherapeutics Inc. stock is a value investor pickWeekly Trading Summary & Low Risk High Win Rate Picks - ulpravda.ru
Is Atara Biotherapeutics Inc. stock safe for conservative investorsProfit Target & Low Risk High Reward Ideas - ulpravda.ru
Why Atara Biotherapeutics Inc. stock attracts global investorsEarnings Trend Report & Risk Controlled Swing Alerts - ulpravda.ru
Atara Stock Plunges To 3-Month Low After FDA Blocks Blood Cancer Drug: Retail's Buying The Dip - MSN
Atara Biotherapeutics prices $16M public offering - MSN
Atara Biotherapeutics Stock (ATRA) Jumps as FDA Decision on Viral Therapy Nears - TipRanks
How Atara Biotherapeutics Inc. stock performs in interest rate cyclesMarket Volume Summary & Fast Moving Stock Trade Plans - ulpravda.ru
Atara revises tab-cel commercialization milestones with Pierre Fabre - MSN
What drives Atara Biotherapeutics Inc stock priceBearish Engulfing Patterns & Build Balanced Portfolio - earlytimes.in
(ATRA) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Atara Biotherapeutics IncEntered fourth amendment with Pierre FabreSEC filing - marketscreener.com
Weekly Analysts’ Ratings Changes for Atara Biotherapeutics (ATRA) - Defense World
How Atara Biotherapeutics Inc. stock performs in stagflationHead and Shoulders Patterns & Easy Tools to Analyze Your Investment Risk - bollywoodhelpline.com
Technical Reactions to ATRA Trends in Macro Strategies - Stock Traders Daily
Biotech Stocks Facing FDA Decision In January 2026 - RTTNews
Can Atara Biotherapeutics Inc. stock deliver consistent earnings growthShort Interest Overview & Superior Trading Portfolio - bollywoodhelpline.com
Atara Biotherapeutics (ATRA) Price Target Increased by 15.69% to 20.06 - Nasdaq
Aug Outlook: Is Atara Biotherapeutics Inc. stock a good choice for value investors2025 Volume Leaders & AI Powered Market Trend Analysis - Улправда
Hedge Fund Bets: Can Atara Biotherapeutics Inc. stock deliver consistent earnings growthInsider Buying & Accurate Buy Signal Alerts - Улправда
Atara Biotherapeutics Earnings Notes - Trefis
Atara Biotherapeutics (ATRA) Sees Price Target Increase by Canac - GuruFocus
Is Atara Biotherapeutics Inc. (AT20) stock worth holding before Fed meetingEarnings Beat & Reliable Breakout Forecasts - Улправда
Can Atara Biotherapeutics Inc. stock surprise with earnings upsideJuly 2025 Drop Watch & Low Risk High Reward Trade Ideas - DonanımHaber
Is Atara Biotherapeutics Inc. stock a good choice for value investorsJuly 2025 Retail & Real-Time Volume Analysis Alerts - Улправда
(ATRA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Is Atara's Tab-Cel The Missing Piece In A Difficult-To-Treat Cancer? - RTTNews
Panic Selling: Why Atara Biotherapeutics Inc stock could be next big winner2025 Buyback Activity & Fast Momentum Stock Entry Tips - moha.gov.vn
Atara Biotherapeutics price target raised to $140 from $131 at Mizuho - MSN
With Atara Biotherapeutics Stock Surging, Have You Considered The Downside? - Trefis
Would You Still Hold Atara Biotherapeutics Stock If It Fell Another 30%? - Trefis
Can Atara Biotherapeutics Stock Recover If Markets Fall? - Trefis
How Atara Biotherapeutics Inc. stock performs during Fed tightening cyclesWeekly Investment Report & Weekly Watchlist of Top Performers - Newser
Can Atara Biotherapeutics Inc. (AT20) stock hit consensus price targetsJuly 2025 Closing Moves & Daily Profit Maximizing Trade Tips - Newser
Is Atara Biotherapeutics Inc. (AT20) stock trading at attractive multiplesJuly 2025 Catalysts & Scalable Portfolio Growth Ideas - Newser
Why Atara Biotherapeutics Inc. (AT20) stock gets analyst attentionPortfolio Gains Summary & Daily Growth Stock Investment Tips - Newser
Is Confidence Futuristic Energetech Limited a Top Alpha Generator for Growth PortfoliosMarket Correction Analysis & Free Real-Time Trading Signals - earlytimes.in
Can Atara Biotherapeutics Inc. stock maintain operating margins2025 Key Lessons & Reliable Breakout Forecasts - Newser
Atara Biotherapeutics (ATRA) Stock Analysis Report | Financials & Insights - Benzinga
Atara Biotherapeutics (NASDAQ:ATRA) Stock Price Passes Below 50 Day Moving AverageHere's Why - MarketBeat
Why Atara Biotherapeutics Inc. (AT20) stock could rally strongly2025 Major Catalysts & Breakout Confirmation Trade Signals - Newser
How robust is Atara Biotherapeutics Inc. (AT20) stock financial positionPortfolio Growth Summary & Accurate Entry and Exit Point Alerts - Newser
Why analysts remain bullish on Atara Biotherapeutics Inc. stockTrade Analysis Report & Expert Curated Trade Setup Alerts - Newser
Can Atara Biotherapeutics Inc. (AT20) stock sustain revenue momentum2025 Trading Recap & Free Long-Term Investment Growth Plans - Newser
Is Atara Biotherapeutics Inc. stock attractive for long term wealth buildingQuarterly Risk Review & Expert Verified Movement Alerts - Newser
Will Atara Biotherapeutics Inc. (AT20) stock benefit from infrastructure billJuly 2025 PostEarnings & Verified Short-Term Plans - Newser
Atara Biotherapeutics: An Empty Pipeline With Little Gas (NASDAQ:ATRA) - Seeking Alpha
Finanzdaten der Atara Biotherapeutics Inc-Aktie (ATRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Atara Biotherapeutics Inc-Aktie (ATRA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Nguyen AnhCo | President and CEO |
Nov 17 '25 |
Sale |
13.19 |
2,915 |
38,437 |
64,974 |
| Grant-Huerta Yanina | Chief Accounting Officer |
Nov 17 '25 |
Sale |
13.19 |
1,804 |
23,788 |
33,454 |
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):